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Relationship Between Salivary Melatonin
and Severity of Periodontal Disease
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Background: Melatonin possesses antioxidant, free-radical
scavenging, and immunoenhancing properties that promote
fibroblast activity and bone regeneration. The aim of this study
was to examine the possible links between salivary melatonin
levels and the severity of periodontal disease using the com-
munity periodontal index (CPI).
Methods: Thirty-seven patients with different degrees of
periodontal disease were studied. Salivary and plasma mela-
tonin levels (by radioimmunoassay), salivary/plasma mela-
tonin ratio, and CPI status were collected for each patient.
The Spearman correlation coefficient was used to analyze
relationships among variables.
Results: Data showed a significant correlation between CPI
and salivary/plasma melatonin ratios. When saliva volume
was controlled for, a significant correlation (P <0.05) was
found between lower salivary melatonin and a worse CPI.
This finding suggests that melatonin may act as a protector
against free radicals produced by inflammatory periodontal
diseases.
Conclusions: Salivary melatonin levels varied according to
the degree of periodontal disease. As the degree of periodontal
disease increased, the salivary melatonin level decreased,
indicating that melatonin may act to protect the body from
external bacterial insults. Therefore, melatonin may be
potentially valuable in the treatment of periodontal diseases,
although further research is required to validate this hypothe-
sis. J Periodontol 2006;77:1533-1538.
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M
elatonin is an indoleamine pro-
duced in various parts of the
body, mainly in the pineal
gland.1 This gland produces melatonin
in a circadian manner, synchronizing
a number of biologic processes in a
24-hour, day–night rhythm. Melatonin
has strong antioxidant effects2 that can
protect cells against inflammatory pro-
cesses and oxidative damage.3-5 These
inflammatory processes include the de-
velopment of certain cancers, ionizing
radiations, metabolism alterations, and
inflammatory responses.6 Melatonin
also plays an immunomodulatory role7
via the secretion of interleukin-2 (IL-2)
and interferon-a (INF-a) and the conse-
quent activation of CD4+ lymphocytes.8
Furthermore, recent studies reported
that melatonin may stimulate the prolif-
eration and synthesis of type I collagen
and promote bone formation.9,10
After release of melatonin into the
blood stream, it diffuses into the saliva.
The proportion of plasma melatonin
passing into the mouth via salivary
glands appears to be relatively stable,
ranging from 24% to 33%.11 It is widely
agreed that 70% of plasma melatonin
is albumin bound. Because only the free
melatonin inplasma is thought tobepres-
ent in saliva, salivary melatonin levels re-
flect the proportion of free-circulating
melatonin.12 Hence, the measurement
of salivary melatonin levels represents
an indirect, non-invasive method for the
assessment of plasma melatonin levels.
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Among other functions, saliva is important for
maintaining oral health status: it lubricates the mouth;
protects against harmful substances in the environ-
ment; modulates oral flora; initiates digestion; and
contributes to tasting, swallowing, and speaking. It
also has various immunological functions because
it contains immunoglobulin A (IgA) antibodies and
other antimicrobial molecules such as lysozyme, lac-
toferrin, and peroxidase. Saliva also protects teeth by
neutralizing acids produced by carbohydrate fermen-
tation.
A reduction in the salivary secretion rate depends
on a number of factors. Unstimulated salivary rates
below 0.1 to 0.2 ml/minute and stimulated rates be-
low 0.5 to 0.7 ml/minute are considered abnormal.
Factors that reduce salivary flow include certain
drugs (e.g., antidepressants, antihypertensives, and
diuretics), systemic diseases (e.g., diabetes and
hypertension), autoimmune diseases (e.g., Sjögren’s
syndrome), and others (e.g., postradiotherapy glan-
dular atrophy and aging). The xerostomia produced
by these factors gives rise to morphological and path-
ophysiological changes in the oral mucosa and may
cause various oral diseases.13
Given the properties of melatonin and its presence
in the mouth via saliva,14 its effect on oral health,
especially periodontal health, warrants further inves-
tigation. Our group previously examined the relation-
ship between salivary melatonin and oral health in
diabetic patients.15 The measurement of melatonin
levels in saliva and plasma should enhance our under-
standing of this interaction. Therefore, the aim of this
study was to examine the relationship between the
level of salivary melatonin and the community peri-
odontal index (CPI) score16 used to assess periodontal
disease status.
MATERIALS AND METHODS
Thirty-seven periodontitis patients, 21 females and 16
males, with a mean age of 55.1 – 0.46 years (range:
18 to 65 years) were recruited at the University of
Granada. Exclusion criteria were as follows: presence
of a systemic neurological disorder (e.g., epilepsy or
schizophrenia), presence of disease with possible ef-
fects on the immune system (e.g., chronic infections
or cancer), and treatment with any drug that might al-
ter melatonin levels. The study was approved by the
University Ethics Committee and was performed in
accordance with the Code of Ethics of the World
Medical Association. Written informed consent was
obtained from all patients.
All study patients underwent an oral examination,
including medical, dental, and caries assessments,
and CPI scores were collected for each patient. The
same dentist performed all examinations. A concor-
dant diagnostic analysis was performed on 11 ran-
domly selected patients by a second examiner,
yielding an interobserver concordance coefficient of
81% for CPI assessments. A physiologist masked to
the oral status of patients measured the plasma and
salivary melatonin levels of each patient.
Measurement of Salivary Melatonin Levels
Participants were asked to refrain from eating after
midnight on the day of the saliva sample collection,
which was carried out around 8:30 am. To stimulate
saliva flow, the patients were asked to chew a piece
of paraffin wax for 7 minutes. The saliva produced
in the first 2 minutes was discarded, and only the sa-
liva generated in the remaining 5 minutes was col-
lected and centrifuged at 3,000 rpm for 20 minutes.
The supernatant was collected and frozen at -20C
until analysis. The amount of melatonin in saliva
was determined by a specific commercial radio-
immunoassay.¶17 The intra- and interassay coeffi-
cients of variation shown by the quality control of
this method were 12.9% and 7.2%, respectively. The
recovery of the added melatonin was 80%, and the
assay sensitivity was 0.04 nmol/l.
Measurement of Serum Melatonin Levels
A 10-ml blood sample was also drawn from the ante-
cubital vein of each patient. This was done at the same
time that the saliva sample was collected. Blood
samples were kept at room temperature for 2 hours
and centrifuged at 3,000 rpm for 10 minutes, and ex-
tracted serum was frozen at -20C.
A commercial radioimmunoassay was employed
to determine the amount of serum melatonin.#18
The intra- and interassay coefficients of variation dis-
played by the quality control of this method were
11.3% and 6.3%, respectively. The recovery of the
added melatonin was 84.4%, and assay sensitivity
was 0.02 nmol/l.
Assessment of Periodontal Disease Severity
Periodontal disease severity was evaluated using the
CPI. The CPI is determined by dividing the mouth into
sextants, each of which contains index teeth. The
sextants are teeth #1 through #5, #6 through #11, #12
through #16, #17 through #21, #22 through #27, and
#28 through #31. The periodontal examination was
carried out using a probe recommended by the World
Health Organization (WHO) with two color markings
at 3.5 and 5.5 mm to record the degree of periodontal
bone loss. CPI codes used for assessing periodontal
status are as follows: code 0 = healthy; code 1 =
bleeding observed, directly or by using a mirror, after
sensing; code 2 = calculus felt during probing, but all
of the black band on the probe was visible; code 3 = a
pocket of 4 to 5 mm (the gingival margin within the
¶ IBL Hamburg, Hamburg, Germany.
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black band on the probe); code 4 = a pocket ‡6 mm
(the black band on the probe was not visible).16
Statistical Analysis
Means and standard deviations were calculated for the
following study variables: patient age, saliva volume,
CPI, salivary melatonin, plasma melatonin, and sali-
vary/plasma melatonin ratio. A multiple regression
analysis was performed to include all variables. The
statistical significance of associations among vari-
ables was determined by using the Spearman correla-
tion coefficient.
RESULTS
Means and standard deviations of measurement vari-
ables were as follows: saliva volume: 2.99 – 0.49 ml;
plasma melatonin level: 8.80 – 1.44 pg/ml; salivary
melatonin level: 2.65 – 0.43 pg/ml; salivary/plasma
melatonin ratio: 0.31 – 0.05; and CPI: 2.57 – 0.42.
Results are shown in Table 1. Older patients had
lower saliva volumes (r = -0.537; P <0.01), higher
CPI scores (r = 0.516; P <0.01), and lower salivary/
plasma melatonin ratios (r = -0.035; P <0.05) com-
pared to younger patients. Patients with a CPI score
of 2 had lower levels of plasma and salivary mela-
tonin. When CPI scores were above 2, corresponding
to a higher mean age, an increase in plasma and
salivary melatonin levels was observed.
A multiple regression analysis showed that age, sa-
liva volume, and gingival index were significantly as-
sociated with the CPI. Gender and smoking had no
correlation with melatonin levels. Age and saliva vol-
ume alone were also included because they were the
only variables significantly related to melatonin level.
A larger saliva volume was associated with a higher
salivary/plasma melatonin ratio (r = 0.369; P <0.05),
even after controlling for the saliva volume (r =
-0.391; P <0.05) (Fig. 1). Patients with higher salivary
and plasma melatonin ratios had lower CPI scores
(r = -0.390; P <0.05) (Table 2).
DISCUSSION
Data from this study indicated that the amount of se-
rum melatonin secreted by salivary glands varied ac-
cording to the severity of the periodontal disease: the
higher the CPI score (worsening of periodontal dis-
ease), the lower the salivary melatonin level and sal-
ivary/plasma melatonin ratio. This finding suggests
that the melatonin may possess the ability to fight
against infection and inflammation, probably due to
its antioxidant, anti-aging, and immunoenhancing
action.6,9,19-22
Periodontal disease is well known to be associated
with an inflammation of the periodontium that de-
stroys periodontal ligament and alveolar bone by re-
sorptive processes. These processes mainly involve
osteoclasts, which are mediated by cytokines and
local factors released by neighboring defensive cells
in response to established bacterial aggression. Mela-
tonin has a critical function in the regulation of pro-
teins implicated as mediators of these processes.
The receptor activator of nuclear factor-kappa B lig-
and (RANKL) is a highly important protein in osteo-
clastic differentiation and proliferation.23 Another
protein, osteoprotegerin (OPG), interferes with its
biologic potential. Liu et al.24 demonstrated that these
proteins play a critical role in the development of peri-
odontal disease, with periodontal bone destruction
produced by the upregulation of RANKL with down-
regulation of OPG. Melatonin can modulate these
events because it is closely related to orchestration
of the molecular triad OPG/RANK/RANKL.25 Thus,
treatment with melatonin, besides stimulating the pro-
liferation, differentiation, and activity of osteoblasts,9
Table 1.










Age 1.000 -0.537† 0.018 -0.048 -0.353* 0.516†
Saliva volume -0.537† 1.000 0.395* 0.389* 0.369* -0.295†
Plasma melatonin 0.018 0.395* 1.000 0.981† 0.118 0.054
Salivary melatonin -0.048 0.389* 0.981† 1.000 0.218 -0.130
Salivary/plasma melatonin ratio -0.353* 0.369* 0.118 0.218 1.000 -0.390*
CPI 0.516† -0.295† 0.054 -0.130 -0.390* 1.000
Spearman correlation analysis (N = 37).
* P <0.05.
† P <0.01.
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reduces the expression of RANKL in vivo and in-
creases the production of OPG by osteoblasts.10 In
this way, melatonin inhibits osteoclastogenesis medi-
ated by an imbalance in favor of RANKL, as occurs in
periodontal disease.
Prostaglandin E2 (PGE2) has also been implicated
in osteoclastic activity in periodontal disease, largely
in relation to periodontal bone loss.26 Melatonin can
also modulate the development of periodontal disease
in this context because it can act on PGE2, thereby in-
hibiting the differentiation of osteoclasts induced by
cell-to-cell contact between osteoblasts and osteo-
clasts.27 Moreover, melatonin can modulate para-
thormone (PTH),28 1a25(OH2)D3, IL-1b, and IL-6,25
all proteins that regulate the resorption process in
periodontal disease and interact with other biologic
agents such as calcitonin29 or IL-2.30 Therefore,
melatonin may inhibit bone resorption31 or promote
bone-marrow cell differentiation.
It is important to note that the stimulation of osteo-
blastic differentiation by melatonin may influence
bone formation through the induction of bone sialo-
protein32 and alkaline phosphatase
and osteocalcin22 that are essential
proteins for bone maturation. Hence,
melatonin may play a major role in
the regulation of the bone resorption-
formation balance in favor of bone
formation.
Melatonin activates several ele-
ments of the immune system that
reduce tissue destruction during the
inflammatory response, either di-
rectly by free radical scavenging or
indirectly by modulating the action
of agents such as cytokines and ad-
hesion molecules, which contribute
to the advance of cell damage.6 In
summary, melatonin may play an
important role in maintaining peri-
odontal health.
The finding of a significant associ-
ation among patient age, decreased
saliva volume, and poor periodontal
status (high CPI) supports the posi-
tive correlation between age-related
xerostomia and poor periodontal
status previously reported by our
group15 and other authors.33 Patients
with a salivary gland dysfunction
Table 2.
Correlation Analyses Among Variables, Controlling for Saliva Volume
Variable Age Plasma Melatonin Salivary Melatonin Salivary/Plasma Melatonin Ratio CPI
Age 1.000 0.290 0.230 0.395* -0.348
Plasma melatonin 0.290 1.000 0.985† 0.148 -0.100
Salivary melatonin 0.230 0.985† 1.000 0.073 0.063
Salivary/plasma melatonin ratio 0.395 0.147 0.734 1.000 -0.391*
CPI -0.348 -0.100 0.063 -0.391* 1.000




Relationship between salivary/plasma melatonin ratio and CPI, controlling for saliva volume.
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always had a low salivary melatonin level, which is
known to result in decreased antioxidant defenses
against the free radicals released during oral inflam-
mation/infection.15 Battino et al.33 observed a de-
crease in the salivary/serum melatonin ratio with
higher age and concluded that melatonin levels in
the oral cavity were reduced by a lower clearance of
serum melatonin by salivary glands. It has been re-
ported that the salivary infiltration rate in many elderly
people is not maintained within 24% to 33% of the nor-
mal range.11 In the present study, normal salivary
melatonin levels were observed in patients when the
saliva volume was also within the normal range. This
observation suggests that salivary glands may control
the amount of melatonin passing from the blood into
the oral cavity. This mechanism is of great importance
because melatonin is not produced in the mouth, and
only serum melatonin can reach it.
With the above background, it can be speculated
that there is a negative association between the sali-
vary melatonin level and periodontal disease severity.
Consequently, the reduction in saliva production with
higher age and the decreased melatonin production in
older adults reflected in low salivary melatonin levels
predispose these individuals to an increased risk of
developing oral and periodontal disease.
To our knowledge, this is one of the first attempts
to examine the influence of salivary melatonin upon
periodontal disease. Data from this study suggest that
melatonin may be able to protect the oral cavity
against free radicals produced by inflammatory dis-
eases. Further research with adequate sample power
is required to fully elucidate the relationship between
serum melatonin and salivary melatonin and its influ-
ence on periodontal health.
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